Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial
Authors:
- The FUTURA/OASIS-8 Trial Group*TGThe FUTURA/OASIS-8 Trial Group*
- P. G. StegPSP. G. Steg
- S. S. JollySJS. S. Jolly
- S. R. MehtaSMS. R. Mehta
- R. AfzalRAR. Afzal
- D. XavierDXD. Xavier
- H.-J. RupprechtHRH.-J. Rupprecht
- J. L. Lopez-SendonJLJ. L. Lopez-Sendon
- A. BudajABA. Budaj
- R. DiazRDR. Diaz
- A. AvezumAAA. Avezum
- P. WidimskyPWP. Widimsky
Open Access
- 30 August 2010
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (12) , 1339-1349
Abstract
In recent years, important advances have been made in the management of non–ST-segment elevation acute coronary syndromes, with new antithrombotic agents, increasing use of percutaneous coronary intervention (PCI) for high-risk cases, and improved secondary prevention. Among newer antithrombotics, fondaparinux, a synthetic factor Xa inhibitor, has recently emerged as an attractive option. Fondaparinux was compared with subcutaneous enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial, a large international randomized trial.1 ST elevation acute coronary syndrome was evaluated in the OASIS-6 trial.2 In OASIS-5, fondaparinux was noninferior to enoxaparin for the primary efficacy outcome of death, myocardial infarction (MI), and refractory ischemia but halved major bleeding leading to a significant mortality reduction with fondaparinux compared with enoxaparin. However, in OASIS-5, there was a small but significant increase in catheter-related thromboses with fondaparinux in patients who underwent cardiac catheterization or PCI. This result prompted the OASIS investigators and guideline committees to recommend the use of unfractionated heparin as adjunctive therapy at the time of PCI for patients with non-ST-segment elevation acute coronary syndromes who were treated with fondaparinux and undergoing PCI3-5; although the range of dosing recommended differs between the European Society of Cardiology guidelines (50-100 U/kg) and American College of Cardiology–American Heart Association guidelines (50-60 U/kg irrespective of glycoprotein IIb/IIIa [GpIIb-IIIa] use), reflecting uncertainty because the dosing is based on analysis of limited retrospective data.Keywords
This publication has 13 references indexed in Scilit:
- Impact of Final Activated Clotting Time After Transradial Coronary Stenting With Maximal Antiplatelet TherapyThe American Journal of Cardiology, 2009
- Predictors of outcome in patients undergoing PCI. Results of the RIVIERA studyInternational Journal of Cardiology, 2008
- Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trialEuropean Heart Journal, 2008
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary SyndromesNew England Journal of Medicine, 2006
- Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized TrialJAMA, 2006
- ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)Catheterization and Cardiovascular Interventions, 2005
- Guidelines for Percutaneous Coronary InterventionsEuropean Heart Journal, 2005
- Relationship between activated clotting time and ischemic or hemorrhagic complications: Analysis of 4 recent randomized clinical trials of percutaneous coronary interventionACC Current Journal Review, 2004
- Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary RevascularizationThe American Journal of Cardiology, 1997
- Low-Dose Heparin for Routine Coronary Angioplasty and StentingThe American Journal of Cardiology, 1996